Polaryx Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PLYX Nasdaq 2830 polaryx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Polaryx Therapeutics, Inc.

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial - May 28th, 2026 6:30 am
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards - May 14th, 2026 7:15 am
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference - Apr 23rd, 2026 6:30 am
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial - Apr 21st, 2026 6:30 am
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care - Apr 15th, 2026 7:15 am
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference - Apr 1st, 2026 6:30 am
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) - Mar 17th, 2026 6:30 am
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events - Mar 12th, 2026 6:30 am
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders - Feb 27th, 2026 6:30 am
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial - Feb 17th, 2026 6:30 am
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ - Feb 10th, 2026 6:30 am
Polaryx Therapeutics Welcomes New Members of the Board of Directors - Feb 5th, 2026 6:30 am
Polaryx to present late-breaker data related to Soteria ahead of trial - Feb 4th, 2026 6:40 am
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch - Feb 3rd, 2026 6:30 am
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX” - Feb 2nd, 2026 6:30 am
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq - Jan 30th, 2026 6:00 am